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O R I G I N A L  A R T I C L E
INTRODUCTION: Posterior reversible encephalopathy 
syndrome (PRES) is a neurological disorder with a wide 
variety of clinical presentations and unique radiological 
findings mainly reflective of vasogenic edema. It most 
commonly involves bilateral parieto-occipital regions of 
the brain[1]. PRES presents clinically with acute 
neurological findings consisting of encephalopathy, 
seizures, visual disturbances, headache, focal 
neurological deficits and status epilepticus[1]. 
Tacrolimus is a calcineurin inhibitor that works by 
inhibiting T-lymphocyte activation and suppresses 
cellular immunity [2]. Tacrolimus is often utilized for the 
prevention of Graft Versus Host Disease (GVHD) in 
patients who have received stem cell transplant (SCT) 
for hematogenous disorders and malignancies. PRES 
associated with Tacrolimus secondary to allogeneic 
stem cell transplant is a relatively rare complication 
documented in both pediatric and adult patients [3-7]. 
The exact incidence of PRES due to tacrolimus therapy 
is unknown. Hammerstrom et al. reported an incidence 
of 1.1% in their retrospective chart review study on 
tacrolimus-associated PRES in hematopoietic 
allogeneic SCT, whereas Wong et al. reported an 
incidence of 1.6% [6,7]. We report the first case of 
tacrolimus-associated PRES in an allogeneic 
hematopoietic stem cell transplant patient from 
Pakistan.
Case Description
An 18-year-old female with a history of acute myeloid 
leukemia (AML) refractory to chemotherapy underwent 
an allogeneic hematopoietic SCT that occurred in 
December, 2018. She was on cyclophosphamide for 
immunosuppression. Her post-transplantation course 
was complicated by hemorrhagic cystitis, reactivation 
of cytomegalovirus (CMV) infection and mild GVHD. 
CMV infection was diagnosed using a Polymerase Chain 
Reaction (PCR) which yielded the CMV quantity of 
3600 IU/ml. Patient also presented with a urinary tract 
infection which the urine culture and sensitivity showed 
to be due to an enterococcus species. Valacyclovir and 
ciprofloxacin were added for her on-going infections 
and her immunosuppressive therapy was switched to 
Tacrolimus 1.5mg once daily. On the third day of 
Tacrolimus treatment, she developed two episodes of 
generalized tonic-clonic seizures which were one hour 
apart, lasted for 15 - 20 seconds and were 
self-aborted. These episodes were followed by postictal 
confusion, visual hallucinations and altered behavior 
compromising of agitation and irritability.
On examination, she had a blood pressure of 110/70 
mm Hg, a heart rate of 102 per minute, a temperature 
of 370C, and a respiratory rate of 18 breaths per 
minute. She was drowsy but oriented to place and 
person only. She obeyed single-step commands and 
had fluent speech. Motor and sensory examinations 
were normal. Neck was supple.
Baseline laboratory investigations were within normal 
limits. Magnetic resonance imaging (MRI) of the brain 
with gadolinium contrast revealed diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences without evidence of diffusion 
restriction, susceptibility signal or contrast 
enhancement (Figure 1). These findings were 
consistent with PRES. Her electroencephalogram (EEG) 
showed diffuse theta and delta slowing as well as 
intermittent generalized delta bursts.She was given 
levetiracetam. Tacrolimus level was 19 ng/mL (normal 
range: 5-20 ng/ml).  Tacrolimus was removed from the 
patient’s medication regimen and she was given 
immunosuppresent cellcept(Mycophenolate mofetil). A 
6 week follow-up visit and neuro-imaging showed 
complete resolution of PRES both clinically and on MRI 
with contrast.
Figure 1: MRI Brain showing diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences and T2 hyperintense signals in 
bilateral cerebellar hemispheres without evidence of 
diffusion restriction, susceptibility signal or 
enhancement, as shown by the blue arrows.
A repeat MRI of the brain on follow-up visit (six weeks 
after discharge) showed complete resolution of PRES 
(Figure 2) along with significant clinical improvement of 
her neurological symptoms. She did not experience 
recurrence of seizures or altered mental status. 
Figure 2: Follow-up MRI Brain showing resolution of 
diffuse hyperintense signals in bilateral cerebral 
hemispheres in T2/FLAIR sequences shown in figure 1.
Discussion:
PRES as a complication of immunosuppressive 
tacrolimus therapy after hematopoietic allogeneic SCT 
is relatively rare with a few documented cases in the 
literature (Table 1). The pathogenesis of PRES includes 
failure of the cerebrovascular auto-regulatory function, 
endothelial dysfunction and breakdown of the 
blood-brain barrier (BBB) all of which lead to 
extravasation of brain plasma resulting in interstitial 
edema [1]. Hypertension is often associated with PRES 
(an average rise of 25% from baseline blood pressure). 
The sympathetic nervous system aids in regulating 
when it is challenged by hypertension, however, the 
posterior parts of the brain are deficient in sympathetic 
innervation, rendering these regions more susceptible 
to vasogenic edema [3]. Similarly, endothelial injury 
leading to PRES is linked with inflammatory conditions 
and cytotoxic effects of certain drugs. (1)
Tacrolimus is used as an immunosuppressive therapy 
and prophylaxis for GVHD after a hematopoietic SCT [2]. 
Tacrolimus is known to cause hypertension which is 
strongly linked to PRES. However, our patient was 
normotensive throughout her hospital course. 
Hypertension is not always present in PRES patients on 
immunosuppressive therapy [4, 7]. 15-20% of patients 
with PRES are found to be normotensive [3]. GVHD itself 
may also be precipitating this condition via endothelial 
vascular cell damage [6], including small and medium 
vessel diseases 6,8]. Generalized tonic-clonic seizures, 
associated with bilateral occipital sharp waves, may be 
seen on EEG. Alternatively, PRES in our patient could 
also be related to cyclophosphamide treatment which 
she received prior to the Tacrolimus therapy. Cases of 
cyclophosphamide-associated PRES have also been 
reported in literature [9]. Furthermore, it is also worth 
addressing that sepsis and infection have also been 
previously associated with PRES since the underlying 
cytokine-mediated mechanisms that are observed in 
sepsis share many similarities with those associated 
with PRES – resulting in increased vascular permeability 
of the brain vessels and interstitial extravasation of 
plasma [9, 10]. Our patient had ongoing infections at 
presentation as well which could’ve compounded to 
development of PRES.
Treatment of this condition depends on withdrawal of 
tacrolimus and supportive management. A significant 
resolution of PRES is seen in all cases. However, 
Hammerstrom et al. found no difference between three 
groups that were either made to stop tacrolimus 
entirely, temporarily stopped tacrolimus for 12 days or 
made to switch to another immunosuppressant [6].As 
the patient was given antiepileptic for seizures initially 
now after resolution of symptoms both clinically and 
radiologically it has  planned to do eeg and considered 
antiepileptics tapering. Although PRES is a mild and 
reversible condition, occasionally with inadequate 
management the condition proves to be irreversible 
and can proceed to coma or death [3, 9]. The mortality 
rate associated with PRES is 3-6% [3].
Conclusion
Tacrolimus-associated PRES in hematopoietic stem cell 
transplant patients is an uncommon but serious 
complication that requires efficient and timely 
management. PRES should be considered as a 
possible cause of any neurological symptoms arising in 
a patient receiving tacrolimus, even with controlled 
blood pressure and normal serum Tacrolimus levels. 
Other contributing factors could include GVHD and 
infections associated with an immunosuppressed 
state. For the resolution of PRES, tacrolimus should be 
immediately withheld and supportive treatments should 
be provided for other precipitating factors.
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compromising of agitation and irritability.
On examination, she had a blood pressure of 110/70 
mm Hg, a heart rate of 102 per minute, a temperature 
of 370C, and a respiratory rate of 18 breaths per 
minute. She was drowsy but oriented to place and 
person only. She obeyed single-step commands and 
had fluent speech. Motor and sensory examinations 
were normal. Neck was supple.
Baseline laboratory investigations were within normal 
limits. Magnetic resonance imaging (MRI) of the brain 
with gadolinium contrast revealed diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences without evidence of diffusion 
restriction, susceptibility signal or contrast 
enhancement (Figure 1). These findings were 
consistent with PRES. Her electroencephalogram (EEG) 
showed diffuse theta and delta slowing as well as 
intermittent generalized delta bursts.She was given 
levetiracetam. Tacrolimus level was 19 ng/mL (normal 
range: 5-20 ng/ml).  Tacrolimus was removed from the 
patient’s medication regimen and she was given 
immunosuppresent cellcept(Mycophenolate mofetil). A 
6 week follow-up visit and neuro-imaging showed 
complete resolution of PRES both clinically and on MRI 
with contrast.
Figure 1: MRI Brain showing diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences and T2 hyperintense signals in 
bilateral cerebellar hemispheres without evidence of 
diffusion restriction, susceptibility signal or 
enhancement, as shown by the blue arrows.
A repeat MRI of the brain on follow-up visit (six weeks 
after discharge) showed complete resolution of PRES 
(Figure 2) along with significant clinical improvement of 
her neurological symptoms. She did not experience 
recurrence of seizures or altered mental status. 
Figure 2: Follow-up MRI Brain showing resolution of 
diffuse hyperintense signals in bilateral cerebral 
hemispheres in T2/FLAIR sequences shown in figure 1.
Discussion:
PRES as a complication of immunosuppressive 
tacrolimus therapy after hematopoietic allogeneic SCT 
is relatively rare with a few documented cases in the 
literature (Table 1). The pathogenesis of PRES includes 
failure of the cerebrovascular auto-regulatory function, 
endothelial dysfunction and breakdown of the 
blood-brain barrier (BBB) all of which lead to 
extravasation of brain plasma resulting in interstitial 
edema [1]. Hypertension is often associated with PRES 
(an average rise of 25% from baseline blood pressure). 
The sympathetic nervous system aids in regulating 
when it is challenged by hypertension, however, the 
posterior parts of the brain are deficient in sympathetic 
innervation, rendering these regions more susceptible 
to vasogenic edema [3]. Similarly, endothelial injury 
leading to PRES is linked with inflammatory conditions 
and cytotoxic effects of certain drugs. (1)
Tacrolimus is used as an immunosuppressive therapy 
and prophylaxis for GVHD after a hematopoietic SCT [2]. 
Tacrolimus is known to cause hypertension which is 
strongly linked to PRES. However, our patient was 
normotensive throughout her hospital course. 
Hypertension is not always present in PRES patients on 
immunosuppressive therapy [4, 7]. 15-20% of patients 
with PRES are found to be normotensive [3]. GVHD itself 
may also be precipitating this condition via endothelial 
vascular cell damage [6], including small and medium 
vessel diseases 6,8]. Generalized tonic-clonic seizures, 
associated with bilateral occipital sharp waves, may be 
seen on EEG. Alternatively, PRES in our patient could 
also be related to cyclophosphamide treatment which 
she received prior to the Tacrolimus therapy. Cases of 
cyclophosphamide-associated PRES have also been 
reported in literature [9]. Furthermore, it is also worth 
addressing that sepsis and infection have also been 
previously associated with PRES since the underlying 
cytokine-mediated mechanisms that are observed in 
sepsis share many similarities with those associated 
with PRES – resulting in increased vascular permeability 
of the brain vessels and interstitial extravasation of 
plasma [9, 10]. Our patient had ongoing infections at 
presentation as well which could’ve compounded to 
development of PRES.
Treatment of this condition depends on withdrawal of 
tacrolimus and supportive management. A significant 
resolution of PRES is seen in all cases. However, 
Hammerstrom et al. found no difference between three 
groups that were either made to stop tacrolimus 
entirely, temporarily stopped tacrolimus for 12 days or 
made to switch to another immunosuppressant [6].As 
the patient was given antiepileptic for seizures initially 
now after resolution of symptoms both clinically and 
radiologically it has  planned to do eeg and considered 
antiepileptics tapering. Although PRES is a mild and 
reversible condition, occasionally with inadequate 
management the condition proves to be irreversible 
and can proceed to coma or death [3, 9]. The mortality 
rate associated with PRES is 3-6% [3].
Conclusion
Tacrolimus-associated PRES in hematopoietic stem cell 
transplant patients is an uncommon but serious 
complication that requires efficient and timely 
management. PRES should be considered as a 
possible cause of any neurological symptoms arising in 
a patient receiving tacrolimus, even with controlled 
blood pressure and normal serum Tacrolimus levels. 
Other contributing factors could include GVHD and 
infections associated with an immunosuppressed 
state. For the resolution of PRES, tacrolimus should be 
immediately withheld and supportive treatments should 
be provided for other precipitating factors.
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compromising of agitation and irritability.
On examination, she had a blood pressure of 110/70 
mm Hg, a heart rate of 102 per minute, a temperature 
of 370C, and a respiratory rate of 18 breaths per 
minute. She was drowsy but oriented to place and 
person only. She obeyed single-step commands and 
had fluent speech. Motor and sensory examinations 
were normal. Neck was supple.
Baseline laboratory investigations were within normal 
limits. Magnetic resonance imaging (MRI) of the brain 
with gadolinium contrast revealed diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences without evidence of diffusion 
restriction, susceptibility signal or contrast 
enhancement (Figure 1). These findings were 
consistent with PRES. Her electroencephalogram (EEG) 
showed diffuse theta and delta slowing as well as 
intermittent generalized delta bursts.She was given 
levetiracetam. Tacrolimus level was 19 ng/mL (normal 
range: 5-20 ng/ml).  Tacrolimus was removed from the 
patient’s medication regimen and she was given 
immunosuppresent cellcept(Mycophenolate mofetil). A 
6 week follow-up visit and neuro-imaging showed 
complete resolution of PRES both clinically and on MRI 
with contrast.
Figure 1: MRI Brain showing diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences and T2 hyperintense signals in 
bilateral cerebellar hemispheres without evidence of 
diffusion restriction, susceptibility signal or 
enhancement, as shown by the blue arrows.
A repeat MRI of the brain on follow-up visit (six weeks 
after discharge) showed complete resolution of PRES 
(Figure 2) along with significant clinical improvement of 
her neurological symptoms. She did not experience 
recurrence of seizures or altered mental status. 
Figure 2: Follow-up MRI Brain showing resolution of 
diffuse hyperintense signals in bilateral cerebral 
hemispheres in T2/FLAIR sequences shown in figure 1.
Discussion:
PRES as a complication of immunosuppressive 
tacrolimus therapy after hematopoietic allogeneic SCT 
is relatively rare with a few documented cases in the 
literature (Table 1). The pathogenesis of PRES includes 
failure of the cerebrovascular auto-regulatory function, 
endothelial dysfunction and breakdown of the 
blood-brain barrier (BBB) all of which lead to 
extravasation of brain plasma resulting in interstitial 
edema [1]. Hypertension is often associated with PRES 
(an average rise of 25% from baseline blood pressure). 
The sympathetic nervous system aids in regulating 
when it is challenged by hypertension, however, the 
posterior parts of the brain are deficient in sympathetic 
innervation, rendering these regions more susceptible 
to vasogenic edema [3]. Similarly, endothelial injury 
leading to PRES is linked with inflammatory conditions 
and cytotoxic effects of certain drugs. (1)
Tacrolimus is used as an immunosuppressive therapy 
and prophylaxis for GVHD after a hematopoietic SCT [2]. 
Tacrolimus is known to cause hypertension which is 
strongly linked to PRES. However, our patient was 
normotensive throughout her hospital course. 
Hypertension is not always present in PRES patients on 
immunosuppressive therapy [4, 7]. 15-20% of patients 
with PRES are found to be normotensive [3]. GVHD itself 
may also be precipitating this condition via endothelial 
vascular cell damage [6], including small and medium 
vessel diseases 6,8]. Generalized tonic-clonic seizures, 
associated with bilateral occipital sharp waves, may be 
seen on EEG. Alternatively, PRES in our patient could 
also be related to cyclophosphamide treatment which 
she received prior to the Tacrolimus therapy. Cases of 
cyclophosphamide-associated PRES have also been 
reported in literature [9]. Furthermore, it is also worth 
addressing that sepsis and infection have also been 
previously associated with PRES since the underlying 
cytokine-mediated mechanisms that are observed in 
sepsis share many similarities with those associated 
with PRES – resulting in increased vascular permeability 
of the brain vessels and interstitial extravasation of 
plasma [9, 10]. Our patient had ongoing infections at 
presentation as well which could’ve compounded to 
development of PRES.
Treatment of this condition depends on withdrawal of 
tacrolimus and supportive management. A significant 
resolution of PRES is seen in all cases. However, 
Hammerstrom et al. found no difference between three 
groups that were either made to stop tacrolimus 
entirely, temporarily stopped tacrolimus for 12 days or 
made to switch to another immunosuppressant [6].As 
the patient was given antiepileptic for seizures initially 
now after resolution of symptoms both clinically and 
radiologically it has  planned to do eeg and considered 
antiepileptics tapering. Although PRES is a mild and 
reversible condition, occasionally with inadequate 
management the condition proves to be irreversible 
and can proceed to coma or death [3, 9]. The mortality 
rate associated with PRES is 3-6% [3].
Conclusion
Tacrolimus-associated PRES in hematopoietic stem cell 
transplant patients is an uncommon but serious 
complication that requires efficient and timely 
management. PRES should be considered as a 
possible cause of any neurological symptoms arising in 
a patient receiving tacrolimus, even with controlled 
blood pressure and normal serum Tacrolimus levels. 
Other contributing factors could include GVHD and 
infections associated with an immunosuppressed 
state. For the resolution of PRES, tacrolimus should be 
immediately withheld and supportive treatments should 
be provided for other precipitating factors.
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compromising of agitation and irritability.
On examination, she had a blood pressure of 110/70 
mm Hg, a heart rate of 102 per minute, a temperature 
of 370C, and a respiratory rate of 18 breaths per 
minute. She was drowsy but oriented to place and 
person only. She obeyed single-step commands and 
had fluent speech. Motor and sensory examinations 
were normal. Neck was supple.
Baseline laboratory investigations were within normal 
limits. Magnetic resonance imaging (MRI) of the brain 
with gadolinium contrast revealed diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences without evidence of diffusion 
restriction, susceptibility signal or contrast 
enhancement (Figure 1). These findings were 
consistent with PRES. Her electroencephalogram (EEG) 
showed diffuse theta and delta slowing as well as 
intermittent generalized delta bursts.She was given 
levetiracetam. Tacrolimus level was 19 ng/mL (normal 
range: 5-20 ng/ml).  Tacrolimus was removed from the 
patient’s medication regimen and she was given 
immunosuppresent cellcept(Mycophenolate mofetil). A 
6 week follow-up visit and neuro-imaging showed 
complete resolution of PRES both clinically and on MRI 
with contrast.
Figure 1: MRI Brain showing diffuse subcortical 
hyperintense signals in bilateral cerebral hemispheres 
in T2/FLAIR sequences and T2 hyperintense signals in 
bilateral cerebellar hemispheres without evidence of 
diffusion restriction, susceptibility signal or 
enhancement, as shown by the blue arrows.
A repeat MRI of the brain on follow-up visit (six weeks 
after discharge) showed complete resolution of PRES 
(Figure 2) along with significant clinical improvement of 
her neurological symptoms. She did not experience 
recurrence of seizures or altered mental status. 
Figure 2: Follow-up MRI Brain showing resolution of 
diffuse hyperintense signals in bilateral cerebral 
hemispheres in T2/FLAIR sequences shown in figure 1.
Discussion:
PRES as a complication of immunosuppressive 
tacrolimus therapy after hematopoietic allogeneic SCT 
is relatively rare with a few documented cases in the 
literature (Table 1). The pathogenesis of PRES includes 
failure of the cerebrovascular auto-regulatory function, 
endothelial dysfunction and breakdown of the 
blood-brain barrier (BBB) all of which lead to 
extravasation of brain plasma resulting in interstitial 
edema [1]. Hypertension is often associated with PRES 
(an average rise of 25% from baseline blood pressure). 
The sympathetic nervous system aids in regulating 
when it is challenged by hypertension, however, the 
posterior parts of the brain are deficient in sympathetic 
innervation, rendering these regions more susceptible 
to vasogenic edema [3]. Similarly, endothelial injury 
leading to PRES is linked with inflammatory conditions 
and cytotoxic effects of certain drugs. (1)
Tacrolimus is used as an immunosuppressive therapy 
and prophylaxis for GVHD after a hematopoietic SCT [2]. 
Tacrolimus is known to cause hypertension which is 
strongly linked to PRES. However, our patient was 
normotensive throughout her hospital course. 
Hypertension is not always present in PRES patients on 
immunosuppressive therapy [4, 7]. 15-20% of patients 
with PRES are found to be normotensive [3]. GVHD itself 
may also be precipitating this condition via endothelial 
vascular cell damage [6], including small and medium 
vessel diseases 6,8]. Generalized tonic-clonic seizures, 
associated with bilateral occipital sharp waves, may be 
seen on EEG. Alternatively, PRES in our patient could 
also be related to cyclophosphamide treatment which 
she received prior to the Tacrolimus therapy. Cases of 
cyclophosphamide-associated PRES have also been 
reported in literature [9]. Furthermore, it is also worth 
addressing that sepsis and infection have also been 
previously associated with PRES since the underlying 
cytokine-mediated mechanisms that are observed in 
sepsis share many similarities with those associated 
with PRES – resulting in increased vascular permeability 
of the brain vessels and interstitial extravasation of 
plasma [9, 10]. Our patient had ongoing infections at 
presentation as well which could’ve compounded to 
development of PRES.
Treatment of this condition depends on withdrawal of 
tacrolimus and supportive management. A significant 
resolution of PRES is seen in all cases. However, 
Hammerstrom et al. found no difference between three 
groups that were either made to stop tacrolimus 
entirely, temporarily stopped tacrolimus for 12 days or 
made to switch to another immunosuppressant [6].As 
the patient was given antiepileptic for seizures initially 
now after resolution of symptoms both clinically and 
radiologically it has  planned to do eeg and considered 
antiepileptics tapering. Although PRES is a mild and 
reversible condition, occasionally with inadequate 
management the condition proves to be irreversible 
and can proceed to coma or death [3, 9]. The mortality 
rate associated with PRES is 3-6% [3].
Conclusion
Tacrolimus-associated PRES in hematopoietic stem cell 
transplant patients is an uncommon but serious 
complication that requires efficient and timely 
management. PRES should be considered as a 
possible cause of any neurological symptoms arising in 
a patient receiving tacrolimus, even with controlled 
blood pressure and normal serum Tacrolimus levels. 
Other contributing factors could include GVHD and 
infections associated with an immunosuppressed 
state. For the resolution of PRES, tacrolimus should be 
immediately withheld and supportive treatments should 
be provided for other precipitating factors.
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